oral semaglutide news Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes FDA approves oral semaglutide for

Double and Triple Incretin-Receptor Agonist Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, has demonstrated superiority compared with GLP1-RA on both glycemic control and weight loss, and achieved favorable effects on hepatic endpoints

It has just completed a phase 2 trial and will soon enter the phase 3 trial to confirm its efficacy further

In fact, adequate protein intake supports sustainable weight loss by preserving metabolism and reducing hunger-driven cravings

After the timer goes off, you can swallow whatever saliva has accumulated in your mouth

To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide